Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

ClinicalTrials.gov ID: NCT00041769

Public ClinicalTrials.gov record NCT00041769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Randomized Controlled Trial Evaluating the Impact of Therapeutic Drug Monitoring (TDM) on Virologic Response to a Salvage Regimen in Subjects With a Normalized Inhibitory Quotient (NIQ) Less Than or Equal to 1 to One or More Protease Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Drug resistance testing can be used to see which anti-HIV drugs are likely to suppress the growth of HIV and to select an anti-HIV regimen for HIV infected patients who have failed previous drug regimens. Therapeutic drug monitoring (TDM) is a process that involves measuring blood levels of a drug and may further increase the benefits that resistance testing offers by optimizing protease inhibitor (PI) drug concentrations. The purpose of this study is to determine whether changing the dose of PIs, as indicated by TDM, reduces the viral load in PI-experienced patients. Hypothesis: Treatment-naive study participants who undergo TDM and whose clinicians' interpret their TDM results and adjust their PI doses will have better virologic response rates and decreased toxicities (and thus better treatment outcomes) than participants who do not undergo TDM.

Study identification

NCT ID
NCT00041769
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
360 participants

Conditions and interventions

Conditions

Interventions

Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2002
Primary completion
Mar 31, 2007
Completion
Jul 31, 2007
Last update posted
Jul 12, 2010

2002 – 2007

United States locations

U.S. sites
46
U.S. states
19
U.S. cities
26
Facility City State ZIP Site status
Univ of Alabama at Birmingham Birmingham Alabama 35924-2050
Univ of Southern California Los Angeles California 90033-1079
UCLA School of Medicine Los Angeles California 90095
Univ of California, San Diego Antiviral Research Center (AVRC) San Diego California 92103
Univ of California San Francisco San Francisco California 94110
San Mateo County AIDS Program Stanford California 94305-5107
Santa Clara Valley Med Ctr Stanford California 94305-5107
Willow Clinic Stanford California 94305-5107
Univ of Colorado Health Sciences Ctr Denver Colorado 80262
Univ of Miami Miami Florida 33136-1013
Univ of Hawaii Honolulu Hawaii 96816-2396
Northwestern Univ Chicago Illinois 60611-3015
The CORE Ctr Chicago Illinois 60612
Methodist Hosp of Indiana Indianapolis Indiana 46202-1261
Indiana Univ Hosp Indianapolis Indiana 46202-5250
Wishard Hosp Indianapolis Indiana 46202
Univ of Maryland, Institute of Human Virology Baltimore Maryland 21201
Johns Hopkins Univ Baltimore Maryland 21287-8106
Harvard (Masschusetts General Hosp) Boston Massachusetts 02114
Beth Israel Deaconess-West Campus Boston Massachusetts 02215
Brigham and Women's Hosp Boston Massachusetts 02215
Univ of Minnesota Minneapolis Minnesota 55455-0392
St. Louis Connect Care St Louis Missouri 63108-2138
Washington Univ (St. Louis) St Louis Missouri 63108-2138
SUNY-Buffalo (Rochester) Buffalo New York 14215
Beth Israel Medical Center New York New York 10003
Chelsea Clinic New York New York 10011
New York University - Bellevue New York New York 10016
Long Beach Memorial (Pediatric) New York New York 10021
Columbia Univ New York New York 10032
Community Health Network Inc Rochester New York 14642
Univ of Rochester Medical Center Rochester New York 14642
University of North Carolina Chapel Hill North Carolina 27514
Duke Univ Med Ctr Durham North Carolina 27710
Ohio State Univ Cincinnati Ohio 45267-0405
Univ of Cincinnati Cincinnati Ohio 45267-0405
Case Western Reserve Univ Cleveland Ohio 44106
Cleveland Clinic Cleveland Ohio 44109-1998
MetroHealth Med Ctr Cleveland Ohio 44109-1998
Univ of Pittsburgh Pittsburgh Pennsylvania 15213
Rhode Island Hosp Providence Rhode Island 02906
Stanley Street Treatment and Resource Providence Rhode Island 02906
The Miriam Hosp Providence Rhode Island 02906
Comprehensive Care Clinic Nashville Tennessee 37203
Univ of Texas, Galveston Galveston Texas 77555-0435
Univ of Washington (Seattle) Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00041769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 12, 2010 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00041769 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →